Overview

A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M

Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
Participant gender:
Summary
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release capsules (in a fixed combination) over a 6-week treatment period and 2 weeks follow up.
Phase:
Phase 2
Details
Lead Sponsor:
Holy Stone Healthcare Co., Ltd
Collaborator:
inVentiv Health Clinical
Treatments:
Mesalamine